Functional magnetic resonance imaging in an animal model of pancreatic cancer

World Journal of Gastroenterology

Volumn 16, Issue 26, 2010, Pages 3292-3298

  Lewandowski, Robert J ^a   Eifler, Aaron C ^a   Bentrem, David J ^a   Chung, Johnathan C ^a   Wang, Dingxin ^a   Woloschak, Gayle E ^a   Yang, Guang Yu ^a   Ryu, Robert ^a   Salem, Riad ^a   Larson, Andrew C ^a   Omary, Reed A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Animal model; Functional magnetic resonance imaging; Pancreatic cancer

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; DIFFUSION WEIGHTED IMAGING; GASTRODUODENAL ARTERY; HISTOPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; RABBIT;

EID: 77954555434     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i26.3292     Document Type: Article

References (12)

1. American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society, 2008
2. Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, Mariotto A, Miller B, Feuer E, Altekruse S, Lewis D, Clegg L, Eisner M, Reichman M, Edwards B. SEER Cancer Statistics Review, 1975-2005. Bethesda: National Cancer Institute, 2008
3. Mayer RJ. Neoplastic disorders. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hanser SL, Jameson JL, editors. Harrison's principles of internal medicine. 16th ed. New York: McGaw-Hill, 2005: 537-539
4. Carpelan-Holmström M, Nordling S, Pukkala E, Sankila R, Lüttges J, Klöppel G, Haglund C. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study reevaluating the data of the Finnish Cancer Registry. Gut 2005; 54: 385-387
5. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996; 223: 273-279
6. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008; 9: 99-132
7. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171
8. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
9. Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, Oku T, Akiyama T, Kusakabe T, Miyanishi K, Niitsu Y. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer 2000; 89: 303-313
10. Ohigashi H, Ishikawa O, Yokayama S, Sasaki Y, Yamada T, Imaoka S, Nakaizumi A, Uehara H. Intra-arterial infusion chemotherapy with angiotensin-II for locally advanced and nonresectable pancreatic adenocarcinoma: further evaluation and prognostic implications. Ann Surg Oncol 2003; 10: 927-934
11. Tanaka T, Sakaguchi H, Anai H, Yamamoto K, Morimoto K, Nishiofuku H, Kichikawa K. Catheter position for adequate intra-arterial chemotherapy for advanced pancreatic cancer: evaluation with CT during arterial injection of contrast material. J Vasc Interv Radiol 2004; 15: 1089-1097
12. Miyanishi K, Ishiwatari H, Hayashi T, Takahashi M, Kawano Y, Takada K, Ihara H, Okuda T, Takanashi K, Takahashi S, Sato Y, Matsunaga T, Homma H, Kato J, Niitsu Y. A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization. Jpn J Clin Oncol 2008; 38: 268-274